Abbott Laboratories 10-Q Summary: Period Ended September 30, 2005
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2005, and the nine months ended on that date. Abbott Laboratories is a global healthcare company with reportable segments in Pharmaceutical Products, Diagnostic Products, Ross Products, and International operations. The company is currently in the process of transferring remaining international operations to its spun-off entity, Hospira, Inc., with 48% of these operations transferred as of the reporting date.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 |
|---|---|---|
| Net Sales | $5,384 million | $16,290 million |
| Operating Earnings | $831 million | $3,061 million |
| Net Earnings (Continuing Ops) | $681 million | $2,396 million |
| Diluted EPS (Continuing Ops) | $0.44 | $1.53 |
| Gross Profit Margin | 50.3% | 51.9% |
| Net Cash from Operating Activities | N/A | $3,687 million |
| Cash and Cash Equivalents | $2,845 million | $2,845 million |
| Working Capital | $2,230 million | $2,230 million |
| Long-Term Debt | $3,049 million | $3,049 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.0% in the third quarter and 16.1% for the nine months compared to 2004. Growth was driven by unit volume, the weaker U.S. dollar (contributing 1.1% to Q3 and 2.0% to YTD sales), and acquisitions (TheraSense, EAS).
- Profitability Decline: Operating earnings decreased 18.7% in the third quarter ($831M vs $1,023M) despite revenue growth. This was primarily due to $203 million in restructuring and impairment charges and a $58 million increase in bad debt reserves.
- Margin Compression: Gross profit margins declined to 50.3% in Q3 from 54.8% in Q3 2004. The decrease was attributed to an unfavorable product mix (increased sales of lower-margin Boehringer Ingelheim products) and restructuring charges.
- Expense Increases: Selling, general, and administrative expenses rose 23.2% in Q3, driven by restructuring charges, bad debt reserves, and increased marketing support for new products like Humira and carotid stents.
- Debt Structure: The current portion of long-term debt increased significantly to $1,606 million from $156 million at year-end 2004, reducing working capital.
Guidance, Outlook, and Risks
- Restructuring Outlook: Abbott expects to incur up to an additional $190 million in future periods for restructuring plans, primarily for accelerated depreciation and asset dispositions. Manufacturing realignment is expected to continue into 2007.
- Tax Contingency: In October 2005, management concluded it would remit an additional $3.7 billion of foreign earnings. An estimated $220 million in additional income tax expense is expected to be recorded in the fourth quarter of 2005.
- Subsequent Event: Abbott reached an agreement with Cambridge Antibody Technologies (CAT) involving fixed and revenue-based royalties. The present value of the fixed portion ($270 million) will be recorded as an intangible asset in Q4 2005.
- Legal Risks: Significant litigation includes antitrust claims regarding Hytrin and Lupron (settlements approved in Q2), OxyContin personal injury suits (195 pending, with Purdue Pharma indemnifying Abbott), and patent disputes regarding Clarithromycin and Sevoflurane. Management believes these will not have a material adverse effect.
- Accounting Changes: Abbott expects to adopt SFAS No. 123 (revised 2004) regarding stock-based compensation on January 1, 2006, which is expected to reduce diluted EPS by approximately 14 cents in 2005.
Investor Verification Checklist
- Q4 Tax Impact: Verify the recording of the $220 million tax expense related to foreign earnings remittance in the upcoming Q4 filing.
- Restructuring Costs: Monitor the execution of the remaining $190 million in expected restructuring charges and their impact on future margins.
- Boehringer Ingelheim Agreement: Confirm the transition of the distribution agreement effective January 1, 2006, and the impact on revenue recognition for the $1.7 billion in prior sales.
- Stock Compensation: Review the Q4 2005 and 2006 filings for the adoption of SFAS 123(R) and the resulting reduction in reported earnings.
- Legal Reserves: Track the status of the Sevoflurane patent appeal and OxyContin litigation to ensure reserves remain adequate.